Pancreatic Cancer Clinical Trials & Research at Providence Medical Group

Pancreatic cancer develops in the pancreatic ductal, acinar, and islet cells. Most pancreatic cancers are adenocarcinoma of pancreatic ductal (PDA) origin. Pancreatic cancer accounts for about 3 percent of all cancers in the U.S. Risk factors that can be changed include tobacco use, obesity, and workplace exposure to certain chemicals.

Providence Medical Group is currently enrolling patients for the following pancreatic cancer clinical trial:


Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Treatment: Pembrolizumab, Olaparib
PI: Yao Yao Pollock, MD
Coordinator: Charity Behrend // charity.behrend@providence.org // (707) 521-3830 ext. 1181
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04548752?term=NCT04548752&draw=2&rank=1
Sponsor: National Cancer Institute


Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Treatment: Pembrolizumab, Olaparib
PI: Yao Yao Pollock, MD
Coordinator: Charity Behrend // charity.behrend@providence.org // (707) 521-3830 ext. 1181
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04548752?term=NCT04548752&draw=2&rank=1
Sponsor: National Cancer Institute

Our Providers

Our Locations